Anthem Biosciences Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 76.2. ROE: 20.8%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 earnings • Updated Feb 28, 2026
What: ₹1,000 crore CAPEX over two years for Unit-4 focusing on high-margin segments
Impact: +₹550 Cr revenue
“Management expressed confidence in their ability to handle projected growth with current and planned capacity additions.”
What: Strategic backward integration in peptide manufacturing including GLP-1 products
Impact: +₹225 Cr revenue
“The management highlighted their backward integration strategy, particularly in peptide manufacturing including GLP-1 products.”
What: Three key growth drivers: GLP-1 products, probiotics import substitution, US biosimilars
Impact: +₹175 Cr revenue
“The company has successfully commercialized 4 new molecules with peak market sales estimates of $10 billion.”
Earnings deceleration risks from management commentary
Trigger: Prolonged geopolitical tensions affecting biotech funding
Impact: -200 bps margin impact
Management view: Management addressed market challenges including customer destocking due to geopolitical uncertainties but noted improving biotech funding environment.
Monitor: RFQ activity levels
Trigger: Full implementation of new labor codes without productivity offsets
Impact: -175 bps margin impact
Management view: Took one-time exceptional item of 25.4 Cr due to new labor codes implementation.
Monitor: Employee cost as % of revenue
Key quotes from recent conference calls
“Discussions covered the ongoing Unit-4 development with a planned ₹1,000 crore CAPEX over two years. The expansion will focus on small molecule manufacturing, peptides, fermentation, and oligonucleotides. — Ajay Bhardwaj”
“We have seen a structural improvement, we have seen margin expansion. — Ajay Bhardwaj”
“Our underlying demand remains robust and our historically strongest quarter, which is the fourth quarter is still ahead and we are confident of delivering a strong finish to this financial year. — Ajay Bhardwaj”
“For FY26 as well as packed margins upwards of 20% in terms of revenue growth, it will be in the mid teens around 15 to 16% is what we will anticipate to end the year with. — Ajay Bhardwaj”
Forward-looking targets from management for FY26-FY27
Revenue Growth Target
15.5%
Implied PAT Growth
20%
OPM Guidance
41.5%
Capex Plan
₹1000 Cr
Key Milestones
• Unit-4 commissioning by Q4 FY27
• Peptide manufacturing integration complete by Q3 FY27
• Specialty ingredients revenue growth to 20%+
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Anthem Biosciences Ltd's latest quarterly results (Dec 2025) show
Anthem Biosciences Ltd's current PE ratio is 76.2x.
Anthem Biosciences Ltd's price-to-book ratio is 13.9x.
Anthem Biosciences Ltd's fundamental strength based on key financial ratios
Anthem Biosciences Ltd has a debt-to-equity ratio of N/A.
Anthem Biosciences Ltd's return ratios over recent years
Anthem Biosciences Ltd's operating cash flow is positive (FY2025).
Anthem Biosciences Ltd currently does not pay a significant dividend (yield 0.00%).
Anthem Biosciences Ltd's shareholding pattern (Dec 2025)
Anthem Biosciences Ltd's promoter holding has remained stable recently.
Anthem Biosciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Anthem Biosciences Ltd has 3 key growth catalysts identified from recent earnings analysis
Anthem Biosciences Ltd has 2 key risks worth monitoring
In Q3 FY26, Anthem Biosciences Ltd's management highlighted
Anthem Biosciences Ltd's management has provided the following forward guidance for FY26-FY27
Based on quantitative research signals, here is why Anthem Biosciences Ltd may be worth studying
Anthem Biosciences Ltd investment thesis summary:
Anthem Biosciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
